GlassScriptPhysician profile
Rahul Pamarthy
NPI 1710543962
$2,727.41
in general payments reported to CMS, 2019-2025
32 companies · $813 in 2025
The $813 reported for 2025 was more than what 86% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.02 · 2022: $200 · 2023: $490 · 2024: $1,161 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865 · Travel and Lodging: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.69 |
| Travel and Lodging | $598.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $526.72 | 2024 | Hemospray |
| Abbvie INC. | $418.87 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $283.57 | 2023-2025 | Entyvio, Eohilia |
| Cook Medical LLC | $159.25 | 2024 | Hemospray |
| Intercept Pharmaceuticals, INC. | $136.72 | 2024-2025 | |
| Seagen INC. | $124.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.37 | 2023 | Reblozyl |
| 3-D Matrix, INC. | $121.17 | 2024 | |
| Janssen Biotech, INC. | $103.50 | 2025 | Tremfya, Simponi Aria, Simponi |
| Eisai INC. | $81.14 | 2023 | |
| Janssen Pharmaceuticals, INC | $74.21 | 2021-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $60.74 | 2024-2025 | Dupixent |
| Alexion Pharmaceuticals, INC. | $50.46 | 2021-2023 | Ultomiris |
| Pfizer INC. | $45.79 | 2025 | |
| Mirum Pharmaceuticals, INC. | $41.20 | 2025 | Livmarli |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $35.78 | 2025 | Ibsrela |
| Novo Nordisk INC | $35.48 | 2025 | Wegovy |
| Curium US LLC | $34.00 | 2024 | Detectnet |
| Merck Sharp & Dohme LLC | $30.13 | 2023 | Dificid |
| Lilly USA, LLC | $28.79 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $27.12 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $24.27 | 2025 | Zenpep |
| Celltrion USA INC. | $22.20 | 2025 | Vegzelma |
| Amgen INC. | $20.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.49 | 2023 | Lynparza |
| Melinta Therapeutics, LLC | $15.82 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.27 | 2025 | Voquezna |
| Sandoz INC. | $15.02 | 2025 | |
| Qol Medical, LLC | $15.00 | 2022 | |
| Incyte Corporation | $13.91 | 2023 | Jakafi, Pemazyre |
| Olympus America INC. | $13.86 | 2025 | Evis Exera III Colonovideoscope |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Pamarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.